{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:45:57Z","timestamp":1784673957968,"version":"3.55.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Linear scleroderma is the most common subtype of localized scleroderma (LoS) in children. It can be associated with extracutaneous manifestations and long-term sequelae. Thus, appropriate diagnosis and management are key to improve the prognosis. In this review, we summarize the most relevant recent publications for the diagnosis, evaluation of disease activity and adequate management of patients with linear scleroderma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>There are specific clinical features that indicate activity in LoS; dermoscopy and Wood's lamp may be useful. Summarizing, scoring methods seem to provide the most adequate assessment of LoS; but several biomarkers that correlate with activity have been studied: E-selectin and IL-2 receptor, CD34+ dermal dendritic cells and Th\/Th1 immunophenotype with decreased T helper (Th2), T regulatory (Tregs), B and natural killer (NK) cells. Recent studies propose hydroxychloroquine monotherapy and tocilizumab as potential therapeutic options.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Clinical evaluation, both physical exam and history, is the most important aspect in diagnosing and assessing activity of linear scleroderma. Clinical scoring methods may be most useful for evaluation of activity; eventually, other biomarkers could be relevant in clinical practice. For most patients with linear scleroderma, the first choice of treatment is methotrexate, but physical therapy, plastic surgery and\/or orthopedic management are key to improve residual limitations and quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Video abstract<\/jats:title>\n            <jats:p>\n                                 http:\/\/links.lww.com\/MOP\/A35.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000785","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T13:36:41Z","timestamp":1559828201000},"page":"482-490","source":"Crossref","is-referenced-by-count":18,"title":["Diagnosis and management of linear scleroderma in children"],"prefix":"10.1097","volume":"31","author":[{"given":"Adriana G.","family":"Pe\u00f1a-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Garc\u00eda-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231208","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.berh.2018.02.004","article-title":"Scleroderma in children","volume":"31","author":"Zulian","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R2-20231208","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clindermatol.2018.04.005","article-title":"Morphea: current concepts","volume":"36","author":"Florez-Pollack","year":"2018","journal-title":"Clin Dermatol"},{"key":"R3-20231208","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archdermatol.2010.239","article-title":"An evaluation of long-term outcomes in adults with pediatric-onset morphea","volume":"146","author":"Saxton-Daniels","year":"2010","journal-title":"Arch Dermatol"},{"key":"R4-20231208","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/art.38853","article-title":"Morphea in adults and children cohort VI: a cross-sectional comparison of outcomes between adults with pediatric-onset and adult-onset morphea","volume":"66","author":"Condie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R5-20231208","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5606\/ArchRheumatol.2018.6578","article-title":"Juvenile scleroderma: a referral center experience","volume":"33","author":"Adrovic","year":"2018","journal-title":"Arch Rheumatol"},{"key":"R6-20231208","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jaad.2013.02.007","article-title":"The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population","volume":"69","author":"Kelsey","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R7-20231208","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00431-018-3144-8","article-title":"Development of minimum standards of care for juvenile localized scleroderma","volume":"177","author":"Constantin","year":"2018","journal-title":"Eur J Pediatr"},{"key":"R8-20231208","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ad.2017.06.021","article-title":"Morphea in childhood: an update","volume":"109","author":"Aranegui","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"R9-20231208","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjd.15001","article-title":"The molecular pathogenesis of morphoea: from genetics to future treatment targets","volume":"177","author":"Saracino","year":"2017","journal-title":"Br J Dermatol"},{"key":"R10-20231208","doi-asserted-by":"crossref","first-page":"614","DOI":"10.5114\/ada.2018.77613","article-title":"The correlation between serum E-selectin levels and soluble interleukin-2 receptors with relation to disease activity in localized scleroderma","volume":"35","author":"Wodok-Wieczorek","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"R11-20231208","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.jid.2017.08.017","article-title":"Early-life gut dysbiosis: a driver of later-life fibrosis?","volume":"137","author":"Ho","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R12-20231208","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2133.2008.08647.x","article-title":"Linear morphoea follows Blaschko's lines","volume":"159","author":"Weibel","year":"2008","journal-title":"Br J Dermatol"},{"key":"R13-20231208","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2017.10.003","article-title":"Wood's lamp as a tool in the evaluation of morphea","volume":"78","author":"Curtiss","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R14-20231208","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jdcr.2018.10.024","article-title":"A case of linear morphea involving the oral cavity","volume":"5","author":"Lopez Pineiro","year":"2019","journal-title":"JAAD Case Rep"},{"key":"R15-20231208","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40257-017-0269-x","article-title":"Morphea and eosinophilic fasciitis: an update","volume":"18","author":"Mertens","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"R16-20231208","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/pde.13336","article-title":"Orthopedic complications of linear morphea: implications for early interdisciplinary care","volume":"35","author":"Schoch","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"R17-20231208","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaad.2018.03.005","article-title":"Inflammatory arthritis in pediatric patients with morphea","volume":"79","author":"Kashem","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R18-20231208","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R19-20231208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11910-019-0929-8","article-title":"Protean neurologic manifestations of two rare dermatologic disorders: sweet disease and localized craniofacial scleroderma","volume":"19","author":"Wallach","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R20-20231208","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3899\/jrheum.171381","article-title":"New features for measuring disease activity in pediatric localized scleroderma","volume":"45","author":"Li","year":"2018","journal-title":"J Rheumatol"},{"key":"R21-20231208","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jdv.13790","article-title":"A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients","volume":"31","author":"Lis-\u015awi\u0119ty","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R22-20231208","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12969-018-0254-9","article-title":"Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma","volume":"16","author":"Agazzi","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"R23-20231208","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ijd.13452","article-title":"The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity","volume":"56","author":"Garcia-Romero","year":"2017","journal-title":"Int J Dermatol"},{"key":"R24-20231208","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/srt.12619","article-title":"Detecting and quantifying activity\/inflammation in localized scleroderma with thermal imaging","volume":"25","author":"Ranosz-Janicka","year":"2019","journal-title":"Skin Res Technol"},{"key":"R25-20231208","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/1346-8138.14713","article-title":"Comparison of 2-D shear wave elastography with clinical score in localized scleroderma: a new method to increase the diagnostic accuracy","volume":"46","author":"Wang","year":"2019","journal-title":"J Dermatol"},{"key":"R26-20231208","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jaad.2010.08.027","article-title":"Activity assessment in morphea using color Doppler ultrasound","volume":"65","author":"Wortsman","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R27-20231208","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jid.2017.04.008","article-title":"Transcriptional and cytokine profiles identify CXCL9 as a biomarker of disease activity in morphea","volume":"137","author":"O\u2019Brien","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R28-20231208","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","article-title":"Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles","volume":"45","author":"Torok","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R29-20231208","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/jdv.15120","article-title":"CD34 stromal expression is inversely proportional to smooth muscle actin expression and extent of morphea","volume":"32","author":"Lee","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R30-20231208","doi-asserted-by":"crossref","first-page":"e0195381","DOI":"10.1371\/journal.pone.0195381","article-title":"Detection of autoimmune antibodies in localized scleroderma by synthetic oligonucleotide antigens","volume":"13","author":"Samuelsen","year":"2018","journal-title":"PLoS One"},{"key":"R31-20231208","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jid.2018.09.025","article-title":"Identifying the signature immune phenotypes present in pediatric localized scleroderma","volume":"139","author":"Mirizio","year":"2019","journal-title":"J Invest Dermatol"},{"key":"R32-20231208","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/pde.13281","article-title":"Discordance of pediatric morphea treatment by pediatric dermatologists","volume":"35","author":"Tollefson","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"R33-20231208","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/CCID.S160923","article-title":"Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast","volume":"11","author":"Noakes","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R34-20231208","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","article-title":"A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma","volume":"54","author":"Kreuter","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R35-20231208","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R36-20231208","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/09546634.2017.1341615","article-title":"The efficacy of methotrexate in the treatment of en coup de sabre (linear morphea subtype)","volume":"29","author":"Rattanakaemakorn","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"R37-20231208","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2340\/00015555-3155","article-title":"Clinical profile of methotrexate-resistant juvenile localised scleroderma","volume":"99","author":"Hardy","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"R38-20231208","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","article-title":"Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology"},{"key":"R39-20231208","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jaad.2019.01.040","article-title":"Treatment of morphea with hydroxychloroquine: a retrospective review of 84 patients at Mayo Clinic, 1996\u20132013","volume":"80","author":"Kumar","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R40-20231208","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology"},{"key":"R41-20231208","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/1346-8138.14161","article-title":"Diagnostic criteria, severity classification and guidelines of localized scleroderma","volume":"45","author":"Asano","year":"2018","journal-title":"J Dermatol"},{"key":"R42-20231208","doi-asserted-by":"crossref","first-page":"20314","DOI":"10.1038\/srep20314","article-title":"Targeting miR-155 to treat experimental scleroderma","volume":"6","author":"Yan","year":"2016","journal-title":"Sci Rep"},{"key":"R43-20231208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/pde.13746","article-title":"Botulinum toxin A for pain reduction in pediatric patients with Parry\u2013Romberg syndrome","volume":"36","author":"Mishra","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"R44-20231208","first-page":"4535804","article-title":"Extensive bone lengthening for a patient with linear morphea","author":"Mishima","year":"2018","journal-title":"Case Rep Orthop"},{"key":"R45-20231208","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/PRS.0000000000004922","article-title":"A 26-year experience with microsurgical reconstruction of hemifacial atrophy and linear scleroderma","volume":"142","author":"Chen","year":"2018","journal-title":"Plast Reconstr Surg"},{"key":"R46-20231208","article-title":"A surgical approach to linear scleroderma using Medpor and dermal fat graft","author":"Kim","year":"2018","journal-title":"Arch Craniofac Surg"},{"key":"R47-20231208","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R48-20231208","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","article-title":"Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology centre and literature review","volume":"17","author":"Martini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R49-20231208","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaad.2018.10.022","article-title":"Morphea and systemic sclerosis are associated with an increased risk of melanoma and nonmelanoma skin cancer","volume":"80","author":"Boozalis","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R50-20231208","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.17312","article-title":"Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma","volume":"180","author":"Kurzinski","year":"2018","journal-title":"Br J Dermatol"},{"key":"R51-20231208","doi-asserted-by":"crossref","first-page":"E90","DOI":"10.1111\/ijd.14401","article-title":"An evaluation of long-term outcomes and recurrence rates in patients with morphea","volume":"58","author":"Litaiem","year":"2019","journal-title":"Int J Dermatol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201908000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T05:03:34Z","timestamp":1702011814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201908000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000785","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}